PureTech Health plc Logo

PureTech Health plc

PTCHF

(1.0)
Stock Price

2,13 USD

-22.02% ROA

-29.4% ROE

-4.26x PER

Market Cap.

481.750.275,00 USD

24.53% DER

0% Yield

-3396.82% NPM

PureTech Health plc Stock Analysis

PureTech Health plc Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

PureTech Health plc Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a low debt to equity ratio (9%), which means it has a small amount of debt compared to the ownership it holds

3 ROE

Negative ROE (-8.87%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (-7.17%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

5 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

6 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

7 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

PureTech Health plc Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

PureTech Health plc Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

PureTech Health plc Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

PureTech Health plc Revenue
Year Revenue Growth
2012 7.932.000
2013 7.019.000 -13.01%
2014 2.012.000 -248.86%
2015 11.740.000 82.86%
2016 4.431.000 -164.95%
2017 650.000 -581.69%
2018 16.371.000 96.03%
2019 8.688.000 -88.43%
2020 8.341.000 -4.16%
2021 9.979.000 16.41%
2022 2.090.000 -377.46%
2023 3.330.000 37.24%
2024 1.152.000 -189.06%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

PureTech Health plc Research and Development Expenses
Year Research and Development Expenses Growth
2012 4.228.000
2013 2.832.000 -49.29%
2014 2.836.000 0.14%
2015 13.408.000 78.85%
2016 41.205.000 67.46%
2017 71.672.000 42.51%
2018 57.293.000 -25.1%
2019 65.166.000 12.08%
2020 61.186.000 -6.5%
2021 81.521.000 24.94%
2022 116.113.000 29.79%
2023 96.235.000 -20.66%
2024 155.712.000 38.2%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

PureTech Health plc General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 3.770.000
2013 3.551.000 -6.17%
2014 7.167.000 50.45%
2015 18.378.000 61%
2016 37.155.000 50.54%
2017 46.283.000 19.72%
2018 24.426.000 -89.48%
2019 34.890.000 29.99%
2020 26.497.000 -31.68%
2021 30.761.000 13.86%
2022 35.669.000 13.76%
2023 25.180.000 -41.66%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

PureTech Health plc EBITDA
Year EBITDA Growth
2012 -5.514.000
2013 -2.596.000 -112.4%
2014 -16.944.000 84.68%
2015 -45.380.000 62.66%
2016 -77.389.000 41.36%
2017 -138.674.000 44.19%
2018 -123.928.000 -11.9%
2019 -94.850.000 -30.66%
2020 -144.757.000 34.48%
2021 -214.896.000 32.64%
2022 -202.718.000 -6.01%
2023 -141.267.000 -43.5%
2024 -258.336.000 45.32%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

PureTech Health plc Gross Profit
Year Gross Profit Growth
2012 7.932.000
2013 7.019.000 -13.01%
2014 2.012.000 -248.86%
2015 11.000.000 81.71%
2016 2.861.000 -284.48%
2017 -70.385.000 104.06%
2018 -61.031.000 -15.33%
2019 -77.160.000 20.9%
2020 8.341.000 1025.07%
2021 -100.492.000 108.3%
2022 -150.343.000 33.16%
2023 -1.603.000 -9278.85%
2024 -6.104.000 73.74%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

PureTech Health plc Net Profit
Year Net Profit Growth
2012 -11.054.000
2013 -4.303.000 -156.89%
2014 -41.643.000 89.67%
2015 -39.393.000 -5.71%
2016 -48.792.000 19.26%
2017 30.869.000 258.06%
2018 -43.654.000 170.71%
2019 421.144.000 110.37%
2020 4.568.000 -9119.44%
2021 -62.709.000 107.28%
2022 -37.064.000 -69.19%
2023 -65.697.000 43.58%
2024 -167.092.000 60.68%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

PureTech Health plc Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 0
2013 0 0%
2014 -2 100%
2015 -2 50%
2016 -2 0%
2017 1 300%
2018 -2 200%
2019 15 107.14%
2020 0 0%
2021 -2 100%
2022 -1 -100%
2023 -2 50%
2024 -6 66.67%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

PureTech Health plc Free Cashflow
Year Free Cashflow Growth
2012 -2.905.000
2013 -9.362.000 68.97%
2014 -10.963.000 14.6%
2015 -33.221.000 67%
2016 -61.709.000 46.17%
2017 -90.859.000 32.08%
2018 -77.286.000 -17.56%
2019 -110.694.000 30.18%
2020 -137.251.000 19.35%
2021 -163.935.000 16.28%
2022 -180.968.000 9.41%
2023 -106.162.000 -70.46%
2024 -80.014.000 -32.68%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

PureTech Health plc Operating Cashflow
Year Operating Cashflow Growth
2012 -1.452.000
2013 -8.774.000 83.45%
2014 -10.543.000 16.78%
2015 -28.611.000 63.15%
2016 -58.033.000 50.7%
2017 -88.688.000 34.56%
2018 -72.796.000 -21.83%
2019 -98.156.000 25.84%
2020 -131.827.000 25.54%
2021 -158.274.000 16.71%
2022 -178.792.000 11.48%
2023 -105.917.000 -68.8%
2024 -80.014.000 -32.37%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

PureTech Health plc Capital Expenditure
Year Capital Expenditure Growth
2012 1.453.000
2013 588.000 -147.11%
2014 420.000 -40%
2015 4.610.000 90.89%
2016 3.676.000 -25.41%
2017 2.171.000 -69.32%
2018 4.490.000 51.65%
2019 12.538.000 64.19%
2020 5.424.000 -131.16%
2021 5.661.000 4.19%
2022 2.176.000 -160.16%
2023 245.000 -788.16%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

PureTech Health plc Equity
Year Equity Growth
2012 -3.354.000
2013 -8.027.000 58.22%
2014 133.687.000 106%
2015 164.053.000 18.51%
2016 92.411.000 -77.53%
2017 63.997.000 -44.4%
2018 166.972.000 61.67%
2019 650.398.000 74.33%
2020 653.539.000 0.48%
2021 584.147.000 -11.88%
2022 547.589.000 -6.68%
2023 458.231.000 -19.5%
2024 306.206.000 -49.65%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

PureTech Health plc Assets
Year Assets Growth
2012 19.185.000
2013 16.766.000 -14.43%
2014 228.028.000 92.65%
2015 326.755.000 30.21%
2016 298.749.000 -9.37%
2017 339.846.000 12.09%
2018 441.763.000 23.07%
2019 941.178.000 53.06%
2020 989.994.000 4.93%
2021 946.006.000 -4.65%
2022 702.647.000 -34.63%
2023 693.973.000 -1.25%
2024 579.950.000 -19.66%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

PureTech Health plc Liabilities
Year Liabilities Growth
2012 22.539.000
2013 24.793.000 9.09%
2014 94.341.000 73.72%
2015 162.702.000 42.02%
2016 206.338.000 21.15%
2017 275.849.000 25.2%
2018 274.791.000 -0.39%
2019 290.780.000 5.5%
2020 336.455.000 13.58%
2021 361.859.000 7.02%
2022 155.058.000 -133.37%
2023 125.583.000 -23.47%
2024 273.744.000 54.12%

PureTech Health plc Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.14
Net Income per Share
-4.73
Price to Earning Ratio
-4.26x
Price To Sales Ratio
129.97x
POCF Ratio
-2.64
PFCF Ratio
-2.34
Price to Book Ratio
1.72
EV to Sales
71.64
EV Over EBITDA
-1.11
EV to Operating CashFlow
-1.29
EV to FreeCashFlow
-1.29
Earnings Yield
-0.23
FreeCashFlow Yield
-0.43
Market Cap
0,48 Bil.
Enterprise Value
0,27 Bil.
Graham Number
35.3
Graham NetNet
1.41

Income Statement Metrics

Net Income per Share
-4.73
Income Quality
1.61
ROE
-0.29
Return On Assets
-0.22
Return On Capital Employed
-0.57
Net Income per EBT
1.38
EBT Per Ebit
0.37
Ebit per Revenue
-65.98
Effective Tax Rate
-0.37

Margins

Sales, General, & Administrative to Revenue
10.85
Research & Developement to Revenue
42.19
Stock Based Compensation to Revenue
1.02
Gross Profit Margin
-6.47
Operating Profit Margin
-65.98
Pretax Profit Margin
-24.58
Net Profit Margin
-33.97

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-7.62
Free CashFlow per Share
-7.63
Capex to Operating CashFlow
-0
Capex to Revenue
0.07
Capex to Depreciation
0.03
Return on Invested Capital
-0.86
Return on Tangible Assets
-0.22
Days Sales Outstanding
202.36
Days Payables Outstanding
104.88
Days of Inventory on Hand
0
Receivables Turnover
1.8
Payables Turnover
3.48
Inventory Turnover
0
Capex per Share
0.01

Balance Sheet

Cash per Share
11,50
Book Value per Share
11,36
Tangible Book Value per Share
11.32
Shareholders Equity per Share
11.71
Interest Debt per Share
3.8
Debt to Equity
0.25
Debt to Assets
0.13
Net Debt to EBITDA
0.9
Current Ratio
3.68
Tangible Asset Value
0,31 Bil.
Net Current Asset Value
0,24 Bil.
Invested Capital
388738000
Working Capital
0,37 Bil.
Intangibles to Total Assets
0
Average Receivables
0,01 Bil.
Average Payables
0,01 Bil.
Average Inventory
0
Debt to Market Cap
0.16

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

PureTech Health plc Dividends
Year Dividends Growth

PureTech Health plc Profile

About PureTech Health plc

PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

CEO
Dr. Bharatt M. Chowrira J.D.,
Employee
90
Address
6 Tide Street
Boston, 02210

PureTech Health plc Executives & BODs

PureTech Health plc Executives & BODs
# Name Age
1 Ms. Daphne Zohar
Founder, Senior Advisor & Board Observer
70
2 Dr. David R. Elmaleh Ph.D.
Co-Founder & Senior Advisor
70
3 Mr. Michael Inbar CPA, M.B.A.
Senior Vice President of Finance
70
4 Mr. Eric Green M.B.A.
Chief Operating Officer
70
5 Ms. Allison Mead Talbot
Head of Communications & Investor Relations
70
6 Mr. Charles Sherwood III, J.D., Ph.D.
General Counsel & Company Secretary
70
7 Mr. Spencer Ball
Senior Vice President of Human Resources
70
8 Dr. Bharatt M. Chowrira J.D., Ph.D.
Chief Executive Officer & Executive Director
70
9 Dr. Eric Elenko Ph.D.
Co-Founder & President
70
10 Dr. Robert S. Langer Jr., Ph.D., ScD
Co-Founder & Non-Executive Director
70

PureTech Health plc Competitors